Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

11.40 +1.46 (+14.69%)
Official Closing Price Updated: 4:10 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 395,214
Open 10.05
Bid (Size) 11.10 (1)
Ask (Size) 11.50 (8)
Prev. Close 9.940
Today's Range 10.00 - 11.52
52wk Range 6.500 - 21.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
Via Investor Brand Network
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire

Performance

YTD
-25.00%
-25.00%
1 Month
+27.23%
+27.23%
3 Month
+13.25%
+13.25%
6 Month
-18.92%
-18.92%
1 Year
-45.05%
-45.05%

More News

Read More
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024
Via InvestorPlace
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
From Cybin Inc.
Via Business Wire
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
Via Investor Brand Network
Exposures Product Safety
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
Via Investor Brand Network
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
Via Investor Brand Network
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
Via Investor Brand Network
Cybin Provides Corporate Update on Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
Via Investor Brand Network
Cybin Announces Completion of Previously Announced Share Consolidation
From Cybin Inc.
Via Business Wire
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
Via Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
Via Investor Brand Network
Exposures Product Safety
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.